ArticleFrontiers in pharmacology2026
Real-world pharmacological treatment of patients with hyperemesis gravidarum in 9 cities of China from 2019 to 2024: a cross-sectional analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Analyze the trends and utilization patterns of medicine for hyperemesis gravidarum (HG) in nine Chinese cities over the past 6 years to provide a reference for clinical practice. Method: The prescription data of drugs for patients diagnosed with HG from 2019-2024 were obtained from the Hospital Prescription Analysis Cooperation Project database of the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association. A cross-sectional analysis was then performed of demographic characteristics, medication types, defined daily doses (DDDs), defined daily costs (DDC), combination therapy and comorbidities for HG. Results: A total of 9097 patients diagnosed with HG, involving 12,505 prescriptions, with a mean age of 29.97 ± 4.35 years. The number of patients in new first-tier cities (Chengdu, Hangzhou, Shenyang, Zhengzhou) exhibited a significant increase. The proportion of advanced maternal age and ≥16 weeks patients has significantly increased. Vitamin B6, metoclopramide, omeprazole, hydrated magnesium hydroxide, and aluminum ranked highest in terms of DDDs. 87% of patients required hospitalization, where combination therapy was commonly observed, predominantly antiemetics combined with antacids/acid reducers. Total prescription costs and Conclusion: From 2019 to 2024, the number of patients with HG increased, while medication costs decreased. This trend is temporally consistent with the progressive implementation of China's centralized drug-procurement program, which may have contributed to alleviating the economic burden on patients. The average age of patients showed no significant change, while the proportion of advanced maternal age cases exhibited an increasing trend, which may be associated with postponed childbearing intentions. Vitamin B6, omeprazole, and metoclopramide were the most frequently used medications, which consistent with the medication structure recommended by national guidelines. Notably, the usage of ondansetron and metoclopramide has risen significantly, while the frequency of antihistamine use remains lower than that of international standards. Furthermore, multiple pregnancies thyroid dysfunction and chronic disease were the most common comorbidities for HG prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.